You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 7,144,884


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,144,884 protect, and when does it expire?

Patent 7,144,884 protects TRINTELLIX and is included in one NDA.

Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-nine patent family members in thirty-six countries.

Summary for Patent: 7,144,884
Patent landscape, scope, and claims:
Title:Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder ##STR00001##
Inventor(s): Ruhland; Thomas (Roskilde, DK), Smith; Garrick Paul (Valby, DK), Bang-Andersen; Benny (Copenhagen, DK), Puschl; Ask (Frederiksberg, DK), Moltzen; Ejner Knud (Gentofte, DK), Andersen; Kim (Ridgewood, NJ)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:10/488,280
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,144,884
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,144,884

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,144,884

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 01466Oct 04, 2001
PCT Information
PCT FiledOctober 02, 2002PCT Application Number:PCT/DK02/00659
PCT Publication Date:April 10, 2003PCT Publication Number: WO03/029232

International Family Members for US Patent 7,144,884

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1436271 ⤷  Subscribe 300652 Netherlands ⤷  Subscribe
European Patent Office 1436271 ⤷  Subscribe C300652 Netherlands ⤷  Subscribe
European Patent Office 1436271 ⤷  Subscribe PA2014013 Lithuania ⤷  Subscribe
European Patent Office 1436271 ⤷  Subscribe 92397 Luxembourg ⤷  Subscribe
European Patent Office 1436271 ⤷  Subscribe CR 2014 00030 Denmark ⤷  Subscribe
European Patent Office 1436271 ⤷  Subscribe 14C0033 France ⤷  Subscribe
European Patent Office 1436271 ⤷  Subscribe C20140012 00108 Estonia ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.